LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sensor for Faster, More Accurate COVID-19 Tests Could Revolutionize Virus Testing

By LabMedica International staff writers
Posted on 30 Mar 2022
Print article
Image: Sensor combines accuracy of PCR testing with speed of rapid antigen tests (Photo courtesy of Johns Hopkins University)
Image: Sensor combines accuracy of PCR testing with speed of rapid antigen tests (Photo courtesy of Johns Hopkins University)

PCR tests are highly accurate, but require complicated sample preparation, with results taking hours or even days to process in a laboratory. On the other hand, rapid tests, which look for the existence of antigens, are less successful at detecting early infections and asymptomatic cases and can lead to erroneous results. Now, a new technology addresses the limitations of these two most widely used types of COVID-19 tests.

A COVID-19 sensor developed at Johns Hopkins University (Baltimore, MD, USA) could revolutionize virus testing by adding accuracy and speed to a process that frustrated many during the pandemic. The sensor, which requires no sample preparation and minimal operator expertise, offers a strong advantage over existing testing methods, especially for population-wide testing.

The sensor is nearly as sensitive as a PCR test and as convenient as a rapid antigen test. During initial testing, the sensor demonstrated 92% accuracy at detecting SARS-COV-2 in saliva samples - comparable to that of PCR tests. The sensor was also highly successful at rapidly determining the presence of other viruses, including H1N1 and Zika. The sensor is based on large area nanoimprint lithography, surface enhanced Raman spectroscopy (SERS), and machine learning. It can be used for mass testing in disposable chip formats or on rigid or flexible surfaces.

Key to the method is the large-area, flexible field enhancing metal insulator antenna (FEMIA) array developed by the researchers. The saliva sample is placed on the material and analyzed using surface-enhanced Raman spectroscopy, which employs laser light to examine how molecules of the examined specimen vibrate. Because the nanostructured FEMIA strengthens the virus's Raman signal significantly, the system can rapidly detect the presence of a virus, even if only small traces exist in the sample. Another major innovation of the system is the use of advanced machine learning algorithms to detect very subtle signatures in the spectroscopic data that allow researchers to pinpoint the presence and concentration of the virus. The sensor material can be placed on any type of surface, from doorknobs and building entrances to masks and textiles. The sensor could potentially be integrated with a hand-held testing device for fast screenings at crowded places like airports or stadiums, according to the researchers. The team continues working to further develop and test the technology with patient samples.

"Our platform goes beyond the current COVID-19 pandemic," added Barman. "We can use this for broad testing against different viruses, for instance, to differentiate between SARS-CoV-2 and H1N1, and even variants. This is a major issue that can't be readily addressed by current rapid tests," said Ishan Barman, an associate professor of mechanical engineering, and one of the senior authors of the study.

"Using state of the art nanoimprint fabrication and transfer printing we have realized highly precise, tunable, and scalable nanomanufacturing of both rigid and flexible COVID sensor substrates, which is important for future implementation not just on chip-based biosensors but also wearables," said David Gracias, a professor of chemical and biomolecular engineering, and one of the senior authors of the study.

Related Links:
Johns Hopkins University 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.